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OBJECTIVES The goal of this study was to determine the long-term effects of estrogen replacement therapy
on the response to endothelin-1 (ET-1) in postmenopausal women with coronary heart
disease.
BACKGROUND It is thought that the vasoconstrictor ET-1 is involved in the development and progression
of atherosclerosis. Estrogen replacement may slow the development of atherosclerosis in
postmenopausal women.
METHODS Nineteen of 20 postmenopausal women randomized to either three months of 2 mg oral
estradiol or placebo completed the double-blind placebo-controlled protocol. Change in
forearm blood flow (FBF) in response to a 60 min brachial arterial infusion of ET-1
(5 pmol/min) was measured before randomization, after one month of randomized therapy
and after three months of therapy using venous occlusion plethysmography.
RESULTS Estrogen treatment had no effect on baseline FBF. Systolic and diastolic blood pressure and
heart rate did not change in response to estrogen therapy or ET-1. Before randomization, in
response to ET-1, FBF was reduced by 221.9% (mean response over 60 min) in the placebo
group and 219.0% in the estradiol group (p 5 0.67). After one month of therapy, the
response was attenuated in the estrogen group, 210.0%, compared with the placebo group,
223.6 (difference in means 13.6%, 95% confidence interval [0.7%, 26.6%], p 5 0.041). After
three months of therapy, there was no difference in response between the placebo group,
227.0%, and estrogen group, 230.2% (p 5 0.65).
CONCLUSIONS In postmenopausal women with coronary heart disease, estrogen therapy inhibits the
vasoconstrictor response to ET-1 after one month of therapy. This effect is lost after three
months of therapy, suggesting that tachyphylaxis to one potentially beneficial action of
estradiol develops during chronic treatment. (J Am Coll Cardiol 2001;37:1367–73) © 2001
by the American College of Cardiology
It is widely believed that estrogen protects against the
development of atherosclerosis in women because natural
ovarian failure and ovariectomy are both associated with an
enhanced risk of coronary heart disease (1). Similarly, a
number of experimental and observational human studies
suggest that estrogen replacement therapy can delay or
prevent the onset of atherosclerosis (2), though the recent
Heart and Estrogen/progestin Replacement Study (HERS)
(3) does not seem to support a role for estrogen in secondary
prevention.
The mechanisms of this putative antiatherosclerotic effect
of estrogen are not fully understood. Beneficial serum lipid
changes (4), inhibition of atherosclerotic plaque forming
cells (5), reduction in low-density lipoprotein oxidation (6)
and a decrease in oxidative stress (7) may play a part but are
unlikely to be the whole explanation (8). Interactions with
other vascular mediators are also potentially important. The
synthesis, release or action of potentially beneficial media-
tors, such as nitric oxide and prostacyclin, may be promoted
(8,9). Conversely the actions of potentially adverse media-
tors may be diminished by estrogen. One such adverse
mediator is endothelin-1 (ET-1), the most potent vasocon-
strictor known and a powerful mitogen (10). Plasma con-
centrations of ET-1 are increased in hypercholesterolemic
subjects (11) and patients with established vascular disease
(12). Furthermore, ET-1 immunoreactivity is enhanced in
the walls of atherosclerotic human vessels (12,13). Increased
expression and activity of endothelin-converting enzyme
(ECE) has also been demonstrated in smooth muscle cells
and macrophages in human atherosclerotic plaques (13,14).
Hence, higher ECE activity has been associated with
progression of atherosclerosis and inhibition of ECE by
phosphoramidon has been shown to retard vascular injury
and atherosclerosis in experimental animals (15). Estrogen
might, therefore, exert its putative antiatherosclerotic effect
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by inhibiting the synthesis and actions of ET-1. There is,
indeed, some evidence that estrogen decreases ET-1 secre-
tion in healthy postmenopausal women (16). There is also
some experimental evidence that estrogen decreases the
vascular actions of ET-1. Estradiol has been shown to
reduce the vasoconstrictor effect of endothelin in coronary
arteries from rabbits, dogs and pigs (17–19). Conversely,
ovariectomy has been reported to increase the vasoconstric-
tive action of ET-1 in rabbit small cerebral arteries (20).
Lastly, the mitogenic effect of ET-1 is attenuated by
estrogen in human umbilical vein cultured smooth muscle
cells (21).
However, the long-term in vivo actions of estrogen on the
vascular response to ET-1 in humans are not known. In this
study, we examined the effects on the vascular response to
ET-1 of three months of estrogen replacement therapy in
postmenopausal women with coronary heart disease.
METHODS
The study was performed with the approval of the Local
Ethics Committee of the West Glasgow Hospitals Univer-
sity NHS Trust. All patients gave written informed consent.
Patients and estrogen therapy. Twenty postmenopausal
women with known coronary heart disease took part in the
study. All patients had either a previously documented
myocardial infarction or angiographically proven coronary
artery disease. They were randomized to three months of
treatment with 2 mg of oral estradiol (Progynova, Schering
Health, Burgess Hill, United Kingdom) or matching pla-
cebo. Treatment could be decreased to 1mg if 2 mg was not
tolerated. Plasma luteinizing hormone (LH) and follicle
stimulating hormone (FSH) concentrations were measured
at baseline to confirm menopausal status, and plasma
estradiol concentrations were measured during the study to
monitor treatment adherence.
Forearm blood flow (FBF) protocols. Each patient was
studied on three occasions: at baseline before randomiza-
tion, after one month of randomized therapy and after three
months of randomized treatment. Patients discontinued
treatment with vasoactive medications for 48 h before each
study day, and aspirin was discontinued for 14 days before
each study day. All other therapies were taken as normal.
Patients abstained from alcohol for 24 h and from food,
caffeine-containing drinks and cigarettes for at least 6 h
before each study. On the study day baseline, FBF mea-
surements were obtained after 45 min of rest, including
30 min of brachial arterial saline infusion, before ET-1 was
infused intra-arterially.
ET-1 infusion. Pharmaceutical grade ET-1 (Clinalfa AG,
Nottingham, United Kingdom) was infused into the non-
dominant brachial artery at a rate of 5 pmol/min for 60 min.
This dose has previously been shown to cause slow onset
vasoconstriction in human forearm resistance vessels (22).
FBF measurements. Studies were performed with patients
lying supine in a quiet clinical laboratory maintained at a
constant temperature between 23°C and 25°C (22–24).
After local anesthesia with 1% lidocaine (Astra Pharmaceu-
ticals, Kings Langley, United Kingdom), a 27-gauge steel
needle (Terumo Medical Corporation, Leuven, Belgium)
was inserted into the nondominant brachial artery and
connected to a constant rate infusion pump (IVAC P1000,
Alaris Medical Systems, San Diego, California) via a 16-
guage epidural catheter (Portex Ltd., Hythe, United King-
dom). Physiological saline solution (0.9%, Baxter Health-
care Ltd., Deerfield, Illinois) was infused at 1 ml/min for at
least 20 min before infusion of the locally acting dose of
ET-1 (see the previous text).
Forearm blood flow was measured simultaneously in the
infused and noninfused arms by venous occlusion plethys-
mography using indium-in-gallium Silastic strain gauges
applied to the widest aspect of each forearm (25). To obtain
blood flow measurements, the hand circulation was ex-
cluded by inflation of wrist cuffs to 220 mm Hg, and
upper-arm cuffs were inflated to 40 mm Hg to obstruct
venous outflow for 12 of every 16 s (22–24). Cuffs were
inflated using rapid cuff inflators (Model E-20; D.E. Ho-
kanson Inc., Bellevue, Washington). Voltage output from
plethysmographs (D.E. Hokanson Inc.) was transferred via
a MacLab 4c analog-to-digital converter (AD Instruments,
Hastings, United Kingdom) to a Macintosh personal com-
puter (PowerMac, Apple Computer Inc., Cupertino, Cali-
fornia) for analysis using Chart software (version 3.2.8, AD
Instruments). Plethysmographic recordings were made for a
period of 2 1/2 minutes at 15 min intervals during saline
infusion, with the final measurement being made 21⁄2 min
immediately before the start of the ET-1 infusion. During
the drug infusion, measurements were made at 10-min
intervals. The last five measurements from each 21⁄2 min
recording period were transferred from Chart to Excel
software (version 7.0, Microsoft Corp., Seattle, Washing-
ton) averaged, and the mean percentage change from
baseline in the ratio of flow between the infused and
noninfused arms was calculated. This uses the noninfused
arm as a contemporaneous control and distinguishes the
effects of drug infusion from any other external or environ-
mental factors (26,27).
Blood pressure and heart rate were manually recorded in
the noninfused arm at 15-min intervals throughout each
study and at the end of the study period.
Statistical methods. All hemodynamic data were recorded
blind to treatment allocation. The study design gave re-
peated measurements at baseline (defined as the time point
Abbreviations and Acronyms
ECE 5 endothelin-converting enzyme
ET-1 5 endothelin-1
FBF 5 forearm blood flow
FSH 5 follicle stimulating hormone
HERS 5 Heart and Estrogen/progestin Replacement
Study
LH 5 luteinizing hormone
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just before ET-1 infusion was commenced) and at 10, 20,
30, 40, 50 and 60 min after infusion, at three periods (study
days): before randomization and at one and three months
after randomization. The statistical model fitted to the
percent change over baseline FBF was a covariance pattern
mixed model assuming a compound symmetry correlation
pattern over the six postinfusion time points (following
Brown et al. [28]). Three separate models were fitted, one
for each time period, with treatment, time and the interac-
tion of treatment and time included as fixed effects. When
no interaction was found, a main effects model was used.
Statistical significance was taken as p , 0.05. All blood flow
results are expressed as mean values with 95% confidence
intervals in the text and mean values 6 1 SEM in the
figures. All other data are tabulated as mean 6 SEM.
RESULTS
Patients. Ten women were randomized to each treatment
group. Nineteen patients completed the study protocol, one
woman withdrawing from the placebo group after the
baseline study because of a urinary tract infection. Details of
these patients are given in Table 1. One woman randomized
to estrogen had to reduce the dose from 2 mg to 1 mg/day
because of breast tenderness (at study day 2, i.e., after one
month of treatment).
Local infusion of ET-1 caused no adverse local or
systemic effects, and patients did not report any discomfort.
Heart rate, blood pressure and FBF in the noninfused
forearm did not change significantly on any of the study
days, confirming that the drug had only local actions on the
forearm vasculature of the infused arm and had no systemic
hemodynamic effects. There were no significant differences
in baseline heart rate and blood pressure between any of the
different study days.
Plasma FSH and LH concentrations. Before randomiza-
tion, mean (6 SEM) FSH concentration was 61.2 6 8 U/L
in the placebo group and 70 6 13 U/L in the estrogen
group (normal postmenopausal concentrations .30 IU/L)
(Table 2).
Before randomization, mean (6 SEM) plasma LH con-
centration was 29.5 6 4 IU/L in the placebo group and
36.7 6 4 IU/L in the estrogen group (normal postmeno-
pausal concentrations .30 IU/L) (Table 2).
Plasma 17b estradiol concentrations. Before randomiza-
tion, mean (6 SEM) plasma estradiol concentration was
60 6 10 pmol/l in the placebo group and 53 6 3 pmol/l in
the active therapy group. Plasma concentrations after one
month and three months of treatment were 55 6 23 and
,50 pmol/l in the placebo group and 381 6 125 and 340 6
93 pmol/l in the estrogen group (Table 2).
Effect of 17b estradiol on baseline FBF. Baseline FBF
before randomization, after one month and after three
months of treatment was 2.50 6 0.21, 2.72 6 0.40, 2.20 6
0.17 ml/min/100 ml forearm volume in the estrogen treat-
ment group (no significant between day differences).
Effect of 17b estradiol on blood pressure. Mean (6
SEM) systolic/diastolic blood pressure before randomiza-
tion, after one month of treatment and after three months of
treatment was: 144 6 8/80 6 3, 143 6 8/79 6 3 and 142 6
8/78 6 3 mm Hg in the placebo group, while in the
estrogen therapy group, the blood pressures were 151 6
7/82 6 3, 148 6 8/80 6 3 and 148 6 6/80 6 3 mm Hg.
There were no significant differences between the groups or
study days.
Effect of 17b estradiol on the vasoconstrictor response to
ET-1. As expected, ET-1 reduced FBF in the infused arm
compared with the noninfused arm, and the average peak
reduction of all 19 patients at the prerandomization visit was
235.96% with a 95% confidence interval of 242.8% to
229.2%. This was similar to that reported previously using
similar doses (22).
There was little evidence of an interaction between
Table 1. Patient Characteristics
Patient Characteristics
17b Estradiol
(n 5 10)
Placebo
(n 5 9)
Age, yrs (mean 6 SD) 65.5 6 7.9 66.4 6 6.6
Hysterectomy, n 4 1
Myocardial infarction, n 8 8
CAD by angiography (no MI), n 2 1
Hypertension, n 3 4
Current smokers, n 3 1
Ex-smokers, n 2 6
Type II disease, n
Diet only 1 0
Drug therapy 1 0
Drug therapy, n
Aspirin 10 8
ACE inhibitor 3 3
Beta-blockade 5 7
Nitrates 9 4
Diuretics 1 0
Serum total cholesterol
concentration at baseline
(mmol/L)
5.97 6 0.33 5.87 6 0.42
ACE 5 angiotensin-converting enzyme; CAD 5 coronary artery disease; MI 5
myocardial infarction.
Table 2. Plasma Hormone Concentrations (mean 6 SEM)
Study Day
17 b Estradiol
(n 5 10)
Placebo
(n 5 9)
LH (IU/L)
Prerandomization 36.7 6 9.0 29.5 6 4.0
After 1 month of therapy 40.0 6 15.2 30.6 6 6.2
After 3 months of therapy 36.9 6 13.9 27.4 6 3.5
FSH (IU/L)
Prerandomization 70.3 6 12.9 61.2 6 7.7
After 1 month of therapy 56.6 6 16.8 60.9 6 7.6
After 3 months of therapy 48.6 6 14.3 62.6 6 7.6
Estradiol (pmol/L)
Prerandomization 53.1 6 3.1 60.0 6 10.0
After 1 month of therapy 381 6 125 55.2 6 22.5
After 3 months of therapy 340 6 93 ,50
FSH 5 follicle stimulating hormone; LH 5 luteinizing hormone.
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treatment and time for any of the periods (study days) (p 5
0.26, p 5 0.80, p 5 0.16 for pre-, one month and three
months after randomization, respectively).
Before randomization, there was a similar mean reduction
in FBF in response to ET-1 in the two treatment groups,
221.9% in the placebo group and 219.0% in the estradiol
group (difference in means 2.9%, 95% confidence interval
[211.1%, 16.9%], p 5 0.67) (Fig. 1). After one month of
therapy, the vasoconstrictor response to ET-1 was signifi-
cantly attenuated in the estrogen treatment group compared
with the placebo treatment group (Fig. 2). The mean
percentage reductions in the ratio of FBF were 23.6% in the
placebo group and 210.0% in the estradiol group (difference
in means 13.6% [0.7%, 26.6%], p 5 0.041). After three
months of therapy, there was no difference in the vasocon-
strictor response to ET-1 in the two treatment groups,
227.0% in the placebo group and 230.2% in the estradiol
group (difference in means 23.2% [217.6%, 11.2%], p 5
0.65) (Fig. 3).
DISCUSSION
We found that ET-1 mediated arterial constriction was
reduced after one month of treatment with estradiol. After
three months of therapy with estrogen, this effect was lost
even though circulation levels of estrogen remained similar
to those recorded after one month of treatment with
estrogen.
Short-term effects of estrogen. Our findings are in keep-
ing with earlier studies in experimental animals. Jiang et al.
(17) found that 17b estradiol at concentrations of between
1 and 30 mmol/L shifted ET-1, calcium and BAY K8644
concentration-dependent contraction curves to the right in
endothelium-denuded coronary arteries taken from male
and nonpregnant female rabbits. Both 17b estradiol and
verapamil also induced dose-dependent relaxation in endo-
thelium intact and endothelium-denuded coronary arteries
submaximally precontracted by ET-1. Lampling et al. (18)
subsequently reported that estradiol at a concentration of 1
mmol/L significantly reduced the contractile response to
ET-1 in isolated pressurized coronary microvessels taken
from the left ventricle of male and female dogs. Estradiol
also produced dose-dependent relaxation of these vessels
after preconstriction with ET-1. This relaxation was signif-
icantly blunted, by about two-thirds, by the combination of
indomethacin and NG-nitro-L-arginine. Lastly, Sudhir
and colleagues (19) found that intracoronary estradiol
(1 nmol/L) reduced the vasoconstrictor response to intra-
coronary ET-1 (1 to 10 pmol/L), in vivo, in pigs. Interest-
ingly, the effects of sarafotoxin, an agonist more selective for
the vascular smooth muscle endothelin type B receptor,
were not reduced by estradiol.
Collectively, these studies in several species of experimen-
tal animals suggest that estradiol modulates the arterial
vasoconstrictor response through endothelium-dependent
Figure 1. Percentage change in forearm blood flow in response to infusion of 5 pmol/min of endothelin-1 (ET-1) for 60 min before randomization to either
placebo or estradiol. Four measurements of forearm blood flow were made before infusion of ET-1 (230, 215, 21 and 0 min). The last time point (0 min)
was taken as baseline. The figure shows subsequent percent change in forearm blood flow during 60 min of ET-1 infusion in each treatment group (placebo
or estradiol). There was no difference between the two treatments (p 5 0.67).
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pathways, possibly involving vasodilator prostaglandins and
nitric oxide. At very high concentrations, an endothelium-
independent effect of estradiol may also be demonstrated.
The mechanism of action of this counterregulatory effect of
estradiol seems to directly or indirectly involve vascular
smooth muscle endothelin type A receptor mediated vaso-
constriction. Our one-month data are consistent with these
animal data but show that the inhibitory effect of estradiol is
apparent with much lower concentrations of this hormone
(in the 300 to 400 pmol/L range). Despite these lower
concentrations of estradiol, the vasconstrictor effect of a
similar concentration of ET-1 to that used by Sudhir et al.
(19) was reduced by approximately half.
Long-term estrogen treatment. What makes our study
unique, however, is that we continued estradiol therapy for
three months and showed that, with chronic dosing, the
inhibitory effect of this hormone on ET-1 mediated vaso-
constriction is completely lost. This observation clearly
demands explanation. The most obvious question to ask is
whether the women in our study continued to take their
hormone treatment. Reported adherence was complete, and
this is substantiated by the persistently high plasma concen-
trations of estradiol in the patients randomized to this
treatment.
A more intriguing question is whether or not tachyphy-
laxis to the effects of estradiol may have occurred with
longer term treatment. Relatively little is known about the
long-term vascular effects of estrogen therapy. Though there
are very many acute studies (29–32), there are very few
reports of estrogen therapy given for more than one month
(33–35). In two well-controlled studies, Lieberman et al.
(33) and Gerhard et al. (34) studied the effect of long-term
estradiol on brachial artery diameter changes, measured
using high-resolution ultrasound, in response to reactive
hyperemia. Lieberman et al. (33) administered estradiol, 1
or 2 mg per day or placebo for nine weeks. In a placebo-
controlled crossover trial, Gerhard et al. (34) gave 0.2 mg of
transdermal estradiol with or without vaginal micronized
progesterone for 14 weeks. In the first study, plasma
estradiol concentrations were not reported, but in the
second study they were approximately 530 pmol/L. In both
studies flow mediated, endothelium-dependent, conduit
artery dilation was enhanced by estradiol therapy. However,
though brachial artery diameter increased, peak reactive
hyperemic flow did not. In a more recent but less well
controlled study, Cagnacci et al. (35) used similar methods
to examine brachial artery diameter changes in response to
reactive hyperemia before and after two months treatment
with 50 mg of transdermal estradiol daily (achieving plasma
concentrations of approximately 140 pmol/L). In contrast
with the two previous groups, these authors did not dem-
onstrate any effect of estradiol on flow mediated vasodila-
tation. Though two of these three studies suggest that
tolerance does not develop to at least some of the vascular
actions of estradiol, there is evidence from experimental
animals that prolonged high concentration exposure does
Figure 2. Percentage change in forearm blood flow in response to infusion of 5 pmol/min of endothelin-1 (ET-1) for 60 min after one month of randomized
treatment. Compared with the placebo group, the estradiol group showed blunted vasoconstrictor response to ET-1 vasoconstriction in response to ET-1
(p 5 0.041). Forearm blood flow is presented as in Figure 1.
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lead to tachyphylaxis (36). If we accept that flow mediated
vasodilation is persistently enhanced during long-term es-
tradiol therapy and that this is related to nitric oxide release,
it would seem that the nitric oxide pathway is not the
mechanism through which estradiol inhibits the forearm
vasoconstrictor response to ET-1 because the latter inhibi-
tion is lost during chronic therapy.
That at least one of the vascular actions of estradiol is lost
during chronic therapy may have important therapeutic
implications. Though there are many possible explanations
for the results of HERS, the sort of tachyphylaxis we have
observed could well be relevant (3).
Study limitations. In this study we did not determine
whether the effect of estrogen was due to alterations in
endothelin receptor density or affinity. A previous study in
porcine arterial endothelial cells suggests that these changes
do not play a role in the effect of estrogen (37).
Summary. We have reported that one month of treatment
with 2 mg oral estradiol substantially reduced the forearm
vasoconstrictor response to ET-1. This effect was lost by
three months. It appears that at least one of the potentially
beneficial vascular actions of estradiol is subject to tachy-
phylaxis.
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